SU.VI.MAX - Supplementation en Vitamines et Mineraux AntioXidant Study
Land
Frankreich
Studienpopulation
12735 Versuchspersonen (Frauen zwischen 35 und 60 Jahren und Männer zwischen 45 und 60 Jahren
Zielgrößen
- Krebs
- KHK
- Mortalität
Studiendauer
1994 bis voraussichtlich?
Design
doppeltblind, randomisiert, placebokontrolliert, Untersuchung zur Primärprävention
Methoden
Tägliche Gabe von
- 120 mg Vitamin C
- 30 mg V vitamin E
- 6 mg Beta-Carotin
- 100 µg Selen
- 20 mg Zink
Dosierung beträgt das 1- bis 3-fache der Recommanded Dietary Allowances
Geplanter Folllow-up: 8 Jahre
Ergebnisse
International Society for Preventive Oncology (Journal)
Effects of a 2 years nutritional doses of antioxidant agents supplementation on biochemical indicators of vitamin status : Preliminary data of the SU.VI.MAX study , a primary prevention trial to reduce cancers and cardio-vascular diseases
International Journal for Vitamin and Nutrition Research
Background and Rationale Behind the SU.VI.MAX Study, a Prevention Trial Using Nutritional Doses of a Combi- nation of Antioxidant Vitamins and Minerals to Reduce Cardiovascular Diseases and Cancers
Medical College of Wisconsin Physicians & Clinics Selenium
Dietary Supplement Fact Sheets
Selenium
Medline
Malvy D.J. et.al. (Abstract)
Effect of two years' supplementation with natural antioxidants on vitamin and trace element status biomarkers: preliminary data of the SU.VI.MAX study.
Cancer Detect Prev 2001;25(5):479-85
Hercberg S. et.al. (Abstract)
“The SU.VI.MAX Study": a primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers. SUpplementation on VItamines et Mineraux AntioXydants.
Food Chem Toxicol 1999 Sep-Oct;37(9-10):925-30
Hercberg S. et.al. (Abstract)
A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study--design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants.
Control Clin Trials 1998 Aug;19(4):336-51
Links zur Studie
Caring for Australiens with Renal Impairment (CARI)
Management of CAD - Treatment of chronic symptomatic cardiovascular disease
Thomson American Health Consultants
Vitamin E for Primary and Secondary Prevention of Heart Disease
Nephrology Pharmacy Associates Publication
Vitamin E—Can it Reduce Cardiovascular Complications in Dialysis Patients?
MedNet Hellas
The effect of antioxidant vitamins on cardiovascular diseases. A critical review
South American Group for Free Radical Research
Selected article of the month: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo control trialE
American College of Physicians (ACP) Journal Club
Vitamin E Reduced Secondary Cardiovascular Disease Events in Patients Receiving Long-Term Hemodialysis
American Medical Association
The Role of Vitamin E in the Prevention of Heart Disease
FDA - Center for Food Safety and Applied Nutrition
Letter Regarding Dietary Supplement Health Claim for Vitamin E and Heart Disease
Medline
Boaz M. et.al.
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.
Lancet 2000 Oct 7;356(9237):1213-8
Comment
Hooper L. et.al.
Antioxidant strategy for cardiovascular diseases.
Lancet 2001 May 26;357(9269):1705-6
| < Vorheriger Beitrag | Nächster Beitrag > |
|---|